Investigating the effects of Vitamin E Tocotrienol on several aspects of Alzheimer’s Disease

The following abstract is taken from a published study and is explained in simple terms to help you understand better. For deeper and technical insights regarding the action of Tocotrienols on Alzheimer’s Disease, kindly refer to the reference link provided at the bottom of this abstract.


It has been observed that cholesterol can play a major role in causing Alzheimer’s disease and it has been observed in several studies that Tocotrienols and not Tocopherols have a good potential in lowering and reducing cholesterol levels. Tocotrienols have shown very positive results against several diseases like Stroke, Fatty liver, certain kinds of cancer, cardiovascular diseases, Alzheimer’s disease, and many more.

Introduction to Alzheimer’s Disease andTocotrienol

Alzheimer’s is the 6th leading cause of death in the United States of America. There are around 5.5 million people in the US, suffering from Alzheimer’s, and around two-thirds of Americans who are suffering from this disease are women. It has been estimated that by the end of 2050, around 16 million people will be diagnosed with Alzheimer’s! Also, Alzheimer’s disease is the 6th leading cause of death in the United States as it kills more people each year than breast cancer and prostate cancer combined!

Alzheimer’s is a spectrum of neurodegenerative illnesses defined by clinical symptoms and changes in the brain. The main characteristic of this disease is progressive dementia where the person keeps losing his memory with time and tends to forget even the slightest of things in just a few minutes. This study has been carried out to investigate the role of Tocotrienols as a neuroprotective agent against Alzheimer’s disease.

How does Tocotrienol fightAlzheimer’s Disease?

The current treatment of Alzheimer’s Disease offers only symptomatic relief to the patients suffering. So, an agent that could help suppress the progression of dementia, which is the major characteristic of Alzheimer’s. Hence, in this study, how Tocotrienol tackles the aspects of Alzheimer’s disease were evaluated.

In the preclinical studies, it was observed that Tocotrienols reduced the oxidative stress by acting as a free-radical scavenger, promoting cellular repair, and mitochondrial function. The results of the study demonstrated that Tocotrienols also prevented glutamate-induced neurotoxicity in the brain cells.

To conclude, Tocotrienols have been observed to have the potential to be used as an agent

Suggested Usage:
Eannatto DeltaGold Tocotrienol contains 90% Delta-Tocotrienol and 10% Gamma-Tocotrienol. One bottle of Eannatto Tocotrienols contains 125g, 60 gels. In studies, 1000mg of dosage of Tocotrienols, have been suggested by researchers for patients suffering from Alzheimer’s Disease. Eannatto Tocotrienol has been derived from the Annatto plant, found in the Amazon which is 100% Tocopherol free. Also, Annatto contains 2x more Tocotrienols than Palm oil and 3x more Tocotrienols than rice bran oil.

which can help prevent the Alzheimer’s disease from occurring and progressing in humans.

Reference for the Study in detail:
  2. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 2010;9:1118–1127. doi: 10.1016/S1474-4422(10)70223-4. [PubMed] [CrossRef] [Google Scholar]
  3. Rosen C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer’s disease—Current concepts. Mol. Neurodegener. 2013;8:20. doi: 10.1186/1750-1326-8-20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  4. Teipel S.J., Grothe M., Lista S., Toschi N., Garaci F.G., Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. N. Am. 2013;97:399–424. doi: 10.1016/j.mcna.2012.12.013. [PubMed] [CrossRef] [Google Scholar]
  5. Cui Y., Liu B., Luo S., Zhen X., Fan M., Liu T., Zhu W., Park M., Jiang T., Jin J.S. Identification of conversion from mild cognitive impairment to Alzheimer’s disease using multivariate predictors. PLoS ONE. 2011;6:e21896. doi: 10.1371/journal.pone.0021896. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  6. Sosa-Ortiz A.L., Acosta-Castillo I., Prince M.J. Epidemiology of dementia and Alzheimer’s disease. Arch. Med. Res. 2012;43:600–608. doi: 10.1016/j.arcmed.2012.11.003. [PubMed] [CrossRef] [Google Scholar]
  7. Alzheimer’s Association 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2015;11:332–384. [PubMed] [Google Scholar]
  8. Weuve J., Hebert L.E., Scherr P.A., Evans D.A. Deaths in the united states among persons with Alzheimer’s disease (2010–2050) Alzheimers Dement. 2014;10:e40–e46. doi: 10.1016/j.jalz.2014.01.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  9. Wimo A., Jonsson L., Bond J., Prince M., Winblad B. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. 2013;9:1–11.e13. doi: 10.1016/j.jalz.2012.11.006. [PubMed] [CrossRef] [Google Scholar]
  10. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007;3:186–191. doi: 10.1016/j.jalz.2007.04.381. [PubMed] [CrossRef] [Google Scholar]
  11. Kumar A., Singh A., Ekavali A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015;67:195–203. doi: 10.1016/j.pharep.2014.09.004. [PubMed] [CrossRef] [Google Scholar]
  12. Ghezzi L., Scarpini E., Galimberti D. Disease-modifying drugs in Alzheimer’s disease. Drug Des. Dev. Ther. 2013;7:1471–1478. [PMC free article] [PubMed] [Google Scholar]
  13. Rondanelli M., Faliva M.A., Peroni G., Moncaglieri F., Infantino V., Naso M., Perna S. Focus on the pivotal role of dietary intake (diet and supplement) and blood levels of tocopherols and tocotrienols in obtaining successful aging. Int. J. Mol. Sci. 2015;16:23227–23249. doi: 10.3390/ijms161023227. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Colombo M.L. An update on Vitamin E, tocopherol, and tocotrienol-perspectives. Molecules. 2010;15:2103–2113. doi: 10.3390/molecules15042103. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  15. Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the Vitamin E of the 21st century: It’s potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010;80:1613–1631. doi: 10.1016/j.bcp.2010.07.043. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  16. Xia W., Mo H. Potential of tocotrienols in the prevention and therapy of Alzheimer’s disease. J. Nutr. Biochem. 2016;31:1–9. doi: 10.1016/j.jnutbio.2015.10.011. [PubMed] [CrossRef] [Google Scholar]
  17. Chin K.Y., Pang K.L., Soelaiman I.N. Tocotrienol, and its role in chronic diseases. Adv. Exp. Med. Biol. 2016;928:97–130. [PubMed] [Google Scholar]
  18. Jiang Q. Natural forms of Vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014;72:76–90. doi: 10.1016/j.freeradbiomed.2014.03.035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


The following abstract is taken from a published study and is explained in simple terms to help you understand better. For deeper and technical insights regarding the action of Tocotrienols on human breast cancer cells, kindly refer to the reference link provided at the bottom of this abstract.